carmustine has been researched along with EHS Tumor in 13 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with mitomycin C and hyperthermia resulted in additive tumor-cell killing, and minocycline administration further increased that effect." | 1.29 | Minocycline as a modulator of chemotherapy and hyperthermia in vitro and in vivo. ( Ara, G; Herman, TS; Holden, SA; Liu, CJ; Teicher, BA, 1994) |
| "Etoposide alone was essentially additive with the alkylating drugs for both tumor-cell and bone-marrow killing, except for BCNU, where a substantial increase in tumor-cell killing occurred (0." | 1.28 | Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo. ( Dezube, B; Frei, E; Herman, TS; Holden, SA; Tanaka, J; Teicher, BA, 1991) |
| "The efficacy of glucan in combination with local radiation therapy was measured using three solid murine tumors of differing abilities to induce a host defense." | 1.26 | Preliminary observations on the effect of glucan in combination with radiation and chemotherapy in four murine tumors. ( Perez, CA; Stewart, CC; Valeriote, FA, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (69.23) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mulcahy, RT | 3 |
| Siemann, DW | 3 |
| Sutherland, RM | 2 |
| Tannock, IF | 1 |
| Teicher, BA | 2 |
| Holden, SA | 2 |
| Liu, CJ | 1 |
| Ara, G | 1 |
| Herman, TS | 2 |
| Tamargo, RJ | 1 |
| Myseros, JS | 1 |
| Epstein, JI | 1 |
| Yang, MB | 1 |
| Chasin, M | 1 |
| Brem, H | 1 |
| Lelieveld, P | 1 |
| Twentyman, PR | 1 |
| Kallman, RF | 1 |
| Brown, JM | 1 |
| Stewart, CC | 1 |
| Valeriote, FA | 1 |
| Perez, CA | 1 |
| Ning, SC | 1 |
| Hahn, GM | 2 |
| Tanaka, J | 1 |
| Dezube, B | 1 |
| Frei, E | 1 |
| Gordon, LF | 1 |
| Kurkjian, SD | 1 |
| Carter, SK | 1 |
| Schabel, FM | 1 |
| Broder, LE | 1 |
| Johnston, TP | 1 |
| Pearson, GR | 1 |
| Redmon, LW | 1 |
| Pearson, JW | 1 |
1 review available for carmustine and EHS Tumor
| Article | Year |
|---|---|
1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Carmustine; Cell Line; Cell-Free System; | 1972 |
1 trial available for carmustine and EHS Tumor
| Article | Year |
|---|---|
1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Carmustine; Cell Line; Cell-Free System; | 1972 |
12 other studies available for carmustine and EHS Tumor
| Article | Year |
|---|---|
Nitrosourea-misonidazole combination chemotherapy: effect on KHT sarcomas, marrow stem cells and gut.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Survival; Cells, Cultured; Colony-Forming Units Ass | 1982 |
In vivo chemosensitization by misonidazole in sensitive and resistant tumor lines.
Topics: Animals; Carmustine; Cell Line; Drug Resistance; Drug Synergism; Humans; Leukemia L1210; Lomustine; | 1983 |
In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU.
Topics: Animals; Body Weight; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Fibrosarcoma; Leukocy | 1980 |
In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU.
Topics: Animals; Carmustine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, C | 1981 |
Minocycline as a modulator of chemotherapy and hyperthermia in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Hyperthermia, Induce | 1994 |
Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Glioma; Ma | 1993 |
The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors. VI. BCNU.
Topics: Animals; Carmustine; Cell Survival; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB | 1979 |
Preliminary observations on the effect of glucan in combination with radiation and chemotherapy in four murine tumors.
Topics: Amphotericin B; Animals; Antineoplastic Agents; Carmustine; Drug Therapy, Combination; Female; Gluca | 1978 |
Combination therapy: lonidamine, hyperthermia, and chemotherapy against the RIF-1 tumor in vivo.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carmustine; Combined Modality Therapy; Fibrosarcoma; Fluo | 1991 |
Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B | 1991 |
Responses of cycling and noncycling cells to 1,3-bis(2-chloroethyl)-1-nitrosourea and to bleomycin.
Topics: Animals; Bleomycin; Carmustine; Cell Division; Cell Survival; Cells, Cultured; Cricetinae; Culture T | 1974 |
Serochemotherapy against a Moloney virus-induced leukemia.
Topics: Animals; Antibodies, Neoplasm; Antibodies, Viral; Carmustine; Fluorescent Antibody Technique; Immuni | 1973 |